Market evolution: Lactams (CN 293379) — 2015–2025

Introduction

This report examines the evolution of EU trade in lactams under Combined Nomenclature code 293379, a residual category covering lactams excluding epsilon-caprolactam, clobazam, methyprylon, and mercury compounds. The product sits within the broader family of heterocyclic compounds with nitrogen hetero-atoms only (CN 2933), and is widely used in pharmaceutical, agrochemical, and polymer applications.

Over the 2015–2025 period, the EU's trade position in this product category underwent a significant transformation. EU trade flows reveal that import values rose by 83.4% while export values increased by 150.1%, yet the trade balance remained persistently negative, widening from −€634 million to −€818 million. Beneath these aggregate figures lie three major dynamics: a structural shift toward Asian suppliers, diverging price trajectories between imports and exports, and a growing vulnerability of the EU to external supply disruptions.

1. The Geographical Reorientation of Trade: From Europe to Asia

The most striking feature of the 2015–2025 period is the dramatic reorientation of the EU's trading partners away from traditional European and transatlantic partners toward Asian suppliers, particularly Singapore, China, and India.

1.1. The Rise of Singapore as a Dominant Supplier

Singapore emerged as the single most significant shift in the EU's import profile. EU imports from Singapore surged from €138 million in 2015 to €862 million in 2025, representing a 524.3% increase. By 2025, Singapore alone accounted for a substantial share of total EU lactam imports, overtaking Switzerland as the leading non-EU supplier. This likely reflects Singapore's role as a hub for chemical trading houses and re-exports of products manufactured elsewhere in Asia, rather than purely domestic production.

1.2. China and India: Steady Ascent

China's export of lactams to the EU grew from €28 million to €284 million (+899.6%), while India expanded from €39 million to €117 million (+198.6%). Together, these two countries represent a growing share of the EU's import basket. This pattern is consistent with the broader trend of active pharmaceutical ingredient (API) and intermediate production shifting toward cost-competitive Asian manufacturers.

Source: Top import partners

1.3. Decline of Switzerland and the United States as Suppliers

Switzerland, historically the EU's largest non-EU supplier of lactams (€414 million in 2015), saw its exports to the EU decline by 49.1% to €211 million by 2025. The United States experienced a similar contraction of 60.8%, falling from €72 million to €28 million. This suggests that European-based multinationals may have progressively relocated parts of their intermediate production to Asia, or that Asian producers have undercut traditional suppliers on price.

1.4. EU Exports: Diversification Toward New Markets

On the export side, the EU also reoriented its destinations. While Switzerland remained a major destination, its share declined sharply (from €244 million to €57 million, −76.6%). In contrast, exports to Singapore surged from €1 million to €84 million (+8,395%), and to China from €7 million to €49 million (+614.3%). Exports to the United States grew by 88.1% to €248 million, and to the United Kingdom by 318.4% to €40 million.

1.5. Intra-EU Specialisation

Within the EU, the specialisation data for 2025 reveals a highly concentrated production landscape. Ireland leads with an RCA of 23.1 and an RSCA of 0.92, indicating a very strong comparative advantage — consistent with Ireland's large pharmaceutical manufacturing base. Belgium (RCA 3.3) and France (RCA 2.0) follow, while most other EU members show little or no specialisation. This concentration suggests that a small number of EU member states bear the burden of maintaining the bloc's production capacity.

2. Diverging Price Dynamics: The EU Traded More Volume at Lower Import Prices

A second key finding concerns the divergence in price trends between imports and exports, which points to a segmentation of the market by value-added level.

2.1. Export Prices Rose, Import Prices Fell

Export unit values increased by 69.4% over the period, from €24,284 per tonne in 2015 to €41,136 per tonne in 2025. Import unit values, by contrast, declined by 8.0%, from €62,719 to €57,719 per tonne. Throughout the period, import prices consistently exceeded export prices, indicating that the EU tends to import higher-value or more specialised lactam variants while exporting lower-value or commodity-grade products.

Source: General Overview

2.2. Volume Growth Outpaced Value Growth on the Import Side

Imports nearly doubled in quantity (+97.1%, from 18,387 to 36,245 tonnes) while their value rose by 83.4%. This confirms that the EU was able to source growing volumes of lactams at relatively stable or declining prices, most likely because Asian suppliers offered competitive pricing compared to European or Swiss sources. On the export side, volume grew by 47.6% while value rose by 150.1%, suggesting the EU shifted its export mix toward higher-value products.

2.3. Price Shocks in 2021–2022

The volatility analysis identifies three notable price shock events. The most significant was a price shock on EU imports from China in 2021, with an abnormality score of 31.4 and a shift of +202.5%, affecting a value share of 61.1% of the relevant trade flow. A second shock hit EU exports to China in 2022 (+153.3% shift). A third, smaller shock affected EU exports to India in 2021 (+1,693% shift, but only 1.3% value share). These shocks are consistent with the post-COVID supply chain disruptions and the 2021–2022 energy price surge that affected chemical manufacturing costs globally.

2.4. Production Decline Aligned with Rising Import Dependence

EU production volumes declined sharply over the period: quantity fell from 901 million kg to 484 million kg (−46.2%), and production value fell from €5.94 billion to €4.67 billion (−21.4%). The decline in production volume was steeper than the decline in production value, indicating that remaining EU production shifted toward higher-value outputs. However, the overall contraction in domestic manufacturing capacity has left the EU increasingly reliant on imports to meet demand.

3. Growing Import Dependence and Structural Vulnerability

The third major dynamic is the EU's increasing vulnerability to external supply disruptions, driven by the combination of declining domestic production and rising import volumes concentrated among a small number of partners.

3.1. From Net Exporter to Net Importer

The net import reliance indicator shifted dramatically from a strongly negative value (−6,086% in 2015, suggesting the EU was a major net exporter) to +77.6% by 2025. This near-complete reversal — a change of over 101% — reflects the structural transformation of the EU's position in the global lactam market. By 2025, the EU was importing the vast majority of its lactam consumption from outside the bloc.

3.2. The Trade Balance Tells a Consistent Story

The EU's trade balance in lactams remained negative throughout the entire period, ranging from −€634 million (2015) to −€818 million (2025). At its worst, the deficit reached −€6.3 billion in a year when import values spiked. The persistence and scale of this deficit underscore the EU's structural dependence on non-EU supply.

Source: Vulnerability indicators

3.3. Concentration and Volatility Risk

Import concentration as measured by the Herfindahl-Hirschman Index (HHI) by value remained moderate (3,541 in 2015 to 3,627 in 2025), but the dominance of Singapore alone — whose import value grew fivefold — suggests increasing reliance on a single transit hub. On the volatility side, imports from Singapore and Mexico showed the highest coefficients of variation (2.25 and 2.86 respectively), indicating that flows from these origins are subject to large year-to-year swings.

3.4. Export Propensity Remains High, but Context Matters

The EU's export propensity remained elevated at 163.7% in 2025, indicating that EU producers continue to export a large share of their output. However, this metric should be interpreted alongside the declining production base: the EU may be exporting specialised, high-value lactams while importing commodity-grade volumes — a pattern typical of mature chemical industries that have offshored lower-margin production.

Conclusion

Over the decade from 2015 to 2025, the EU's trade in lactams (CN 293379) underwent a fundamental transformation. The bloc shifted from a position of strong net export capacity to one of significant import dependence, with the net import reliance indicator moving from −6,086% to +77.6%. This shift was driven by a combination of declining domestic production (−46.2% in volume) and a rapid expansion of imports from Asian suppliers, led by Singapore (+524%), China (+900%), and India (+199%).

At the same time, the EU managed to reorient its exports toward higher-value products, with export unit values rising 69.4% while import prices declined slightly. This suggests a bifurcation of the EU's role: increasingly a niche exporter of specialised lactams, while relying on Asia for bulk supply. The 2021–2022 price shocks — particularly on Chinese imports — highlight the vulnerability inherent in this configuration.

For policymakers, the key takeaway is that the EU's lactam supply chain has become both more geographically concentrated and more exposed to external disruptions, even as EU producers have maintained competitiveness in higher-value segments. Monitoring the continued evolution of this trade pattern will be essential for assessing Europe's chemical supply security in the years ahead.